News & Analysis on Clinical Trial Services & Contract Research And Development
An active pharmaceutical ingredient (API) pilot project, implemented by the Pharmacopoeial Discussion Group (PDG) last summer and aimed at harmonising API monographs, should generate its first results before the end of the year.
The therapeutic index of Tekmira’s SNALP technology, which has been designed to deliver siRNA, has been improved by 5-10 times, according to new data.
UK contract services provider Melbourn Scientific has extended its service portfolio, predicting that demand for outsourced early R&D will increase in times of economic gloom.
Pharma Phacts
This week in-PharmaTechnologist's Pharma Phacts podcast focuses on a nanotechnology method that could produce more effective barrier packaging using less material.
Outsourcing-Pharma.com presents its periodic round-up of executive appointments in the contract services sector.
Pandemic influenza vaccine manufacturing technology will be made available to developing countries through a collaboration between the WHO and Schering-Plough.
Pfizer’s primary care business unit has dropped two Phase III candidates, further reducing the drug giant’s product pipeline and raising more questions about its R&D decisions.